Meta-analysis of calcineurin-inhibitor-sparing regimens in kidney transplantation

Area of Science:

• Nephrology
• Immunosuppression
• Transplantation Medicine

Background:

• Calcineurin inhibitors are standard in kidney transplantation but cause adverse effects.
• The efficacy of calcineurin-inhibitor-sparing strategies remains uncertain.
• Reducing calcineurin inhibitor exposure aims to mitigate side effects while maintaining graft survival.

Purpose of the Study:

• To assess the efficacy and outcomes of calcineurin-inhibitor-sparing strategies in kidney transplantation.
• To evaluate the impact of reduced calcineurin inhibitor exposure on graft failure, graft function, and adverse events.

Main Methods:

• A meta-analysis of randomized controlled trials (RCTs) published between 1966 and 2010.
• Searched Medline, Embase, and Cochrane Register of Controlled Trials for relevant studies.
• Included 56 studies with data from 11,337 renal transplant recipients comparing de novo calcineurin-inhibitor-sparing regimens to calcineurin-inhibitor-based regimens.

Main Results:

• Contemporary agents (belatacept, tofacitinib) with mycophenolate decreased overall graft failure (OR 0.61).
• Minimization of calcineurin inhibitors reduced graft failure (OR 0.73) and delayed graft function (OR 0.89).
• Mammalian target of rapamycin (mTOR) inhibitors with mycophenolate increased graft failure (OR 1.43); however, newer protocols did not increase acute rejection.

Conclusions:

• Calcineurin-inhibitor-sparing strategies are associated with improved clinical outcomes, including reduced graft failure and better graft function.
• These strategies also led to less delayed graft function and fewer instances of new-onset diabetes.
• Reducing calcineurin inhibitor exposure immediately post-kidney transplantation appears to be a viable strategy for improving patient outcomes.